paroxetine has been researched along with Diabetic Angiopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wheatcroft, SB | 1 |
| Coletta, C; Gerö, D; Módis, K; Oláh, G; Suzuki, K; Szabo, C; Szoleczky, P | 1 |
2 other study(ies) available for paroxetine and Diabetic Angiopathies
| Article | Year |
|---|---|
Teaching an old drug new tricks: can paroxetine ease the burden of cardiovascular disease in diabetes?
Topics: Animals; Antioxidants; Cardiovascular Agents; Diabetic Angiopathies; Endothelium, Vascular; Humans; Male; Paroxetine | 2013 |
Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction.
Topics: Animals; Antidepressive Agents, Second-Generation; Antioxidants; Aorta, Thoracic; Cardiovascular Agents; Cell Line; Cell Nucleus; Cytoplasm; Diabetic Angiopathies; DNA Damage; DNA, Mitochondrial; Endothelium, Vascular; Humans; In Vitro Techniques; Male; Mice; Mitochondria; Oxidative Stress; Paroxetine; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Selective Serotonin Reuptake Inhibitors | 2013 |